DSG3 and pemphigus vulgaris: Such an approach has demonstrated exciting results in vitro and in vivo in the case of CAAR T cells redirected against desmogelin-3 (DSG3) as a therapeutic approach for pemphigus vulgaris where B cells secrete autoantibodies against DSG3, which is an antigen expressed in the skin and mucosa (146).